March 2024
1. PADONOU F, Vanhulst T, Langouo-Fontsa MD
   Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?
   Curr Opin Oncol. 2024;36:63-68.
   

   >> Share

   
   January 2024
2. BENHIMA N, Belbaraka R, Fontsa ML
   Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.
   Curr Opin Oncol. 2024 Jan 3. doi: 10.1097/CCO.0000000000001014.
   

   >> Share

   
   September 2023
3. KINDT N, Kotecki N, Awada A
   Preclinical models to understand the biology and to discover new targets in brain metastases.
   Curr Opin Oncol. 2023;35:436-440.
   

   >> Share

   
   July 2023
4. SAUDE-CONDE R, Nguyen D, Hendlisz A
   Immunotherapies in non-metastatic gastrointestinal cancers.
   Curr Opin Oncol. 2023;35:334-346.
   

   >> Share

   
   March 2023
5. D'ALISE AM, Scarselli E
   Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.
   Curr Opin Oncol. 2023;35:94-99.
   

   >> Share

   
   
6. SCHWARZE JK, Geeraerts X, Tuyaerts S, Neyns B, et al
   Current "state of the art" on dendritic cell-based cancer vaccines in melanoma.
   Curr Opin Oncol. 2023;35:87-93.
   

   >> Share

   
   January 2023
7. ELLINGSEN EB, Bjorheim J, Gaudernack G
   Therapeutic cancer vaccination against telomerase: clinical developments in melanoma.
   Curr Opin Oncol. 2023 Jan 17. doi: 10.1097/CCO.0000000000000922.
   

   >> Share

   
   September 2022
8. BAEUERLE PA, Wesche H
   T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
   Curr Opin Oncol. 2022;34:552-558.
   

   >> Share

   
   March 2022
9. PLUMAS J
   Harnessing dendritic cells for innovative therapeutic cancer vaccines.
   Curr Opin Oncol. 2022;34:161-168.
   

   >> Share

   
   January 2022
10. DEVAUX A, Baurain JF
    Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors.
    Curr Opin Oncol. 2022 Jan 25. pii: 00001622-900000000-98953.
    

    >> Share

    
    
11. AWADA G, Neyns B
    Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
    Curr Opin Oncol. 2022 Jan 19. pii: 00001622-900000000-98954.
    

    >> Share

    
    
12. KRAYEM M, Ghanem GE, Van Gestel D
    Recent advances in radiosensitivity determinants in melanoma.
    Curr Opin Oncol. 2022 Jan 10. pii: 00001622-900000000-98957.
    

    >> Share

    
    March 2021
13. MOREIRA A, Lebbe C, Heinzerling L
    MAPK blockade, toxicities, pathogenesis and management.
    Curr Opin Oncol. 2021;33:139-145.
    

    >> Share

    
    January 2021
14. TROJANIELLO C, Vitale MG, Ascierto PA
    Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
    Curr Opin Oncol. 2021;Publish Ahead of Print.
    

    >> Share

    
    December 2020
15. DUMAZ N, Lebbe C
    New perspectives on targeting RAF, MEK and ERK in melanoma.
    Curr Opin Oncol. 2020;Publish Ahead of Print.
    

    >> Share

    
    
16. TETU P, Vercellino L, Reger de Moura C, Baroudjian B, et al
    Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data.
    Curr Opin Oncol. 2020 Dec 9. doi: 10.1097/CCO.0000000000000706.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share